Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it... It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.
- Mechanism
- Curator reviewed
IDN-6556 significantly improves markers of liver damage in patients infected with the Hepatitis C virus (HCV), an infection that affects up to 170m patients worldwide. IDN-6556 represents a new class of drugs that protect the liver from inflammation and cellular damage induced by viral infections and other causes. Various studies have also shown that it significantly lowers aminotransferase activity in HCV patients and appeared to be well tolerated.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C), liver disease, and transplantation (organ or tissue).Curator reviewed
- Formula / weight
- C26H27F4N3O7 · 569.51 g/mol (avg)
- Code names
- IDN-6556 · PF-3491390
Resolves to
SCVHJVCATBPIHN-SJCJKPOMSA-NSMILESC[C@H](NC(=O)C(=O)NC1=C(C=CC=C1)C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COC1=C(F)C(F)=CC(F)=C1FWhat you can answer from here — as of February 21, 2021
Which drugs share a target with Emricasan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account